This article has Open Peer Review reports available.
Quick identification of acute chest pain patients study (QICS)
© Willemsen et al; licensee BioMed Central Ltd. 2009
Received: 04 August 2008
Accepted: 15 June 2009
Published: 15 June 2009
Patients with acute chest pain are often referred to the emergency ward and extensively investigated. Investigations are costly and could induce unnecessary complications, especially with invasive diagnostics. Nevertheless, chest pain patients have high mortalities. Fast identification of high-risk patients is crucial. Therefore several strategies have been developed including specific symptoms, signs, laboratory measurements, and imaging.
The Quick Identification of acute Chest pain Study (QICS) will investigate whether a combined use of specific symptoms and signs, electrocardiography, routine and new laboratory measures, adjunctive imaging including electron beam (EBT) computed tomography (CT) and contrast multislice CT (MSCT) will have a high diagnostic yield for patients with acute chest pain. All patients will be investigated according a standardized protocol in the Emergency Department. Serum and plasma will be frozen for future analysis for a wide range of biomarkers at a later time point. The primary endpoint is the safe recognition of low-risk chest pain patients directly at presentation. Secondary endpoint is the identification of a wide range of sensitive predictive clinical markers, chemical biomarkers and radiological markers in acute chest pain patients. Chemical biomarkers will be compared to quantitative CT measurements of coronary atherosclerosis as a surrogate endpoint. Chemical biomarkers will also be compared in head to head comparison and for their additional value.
This will be a very extensive investigation of a wide range of risk predictors in acute chest pain patients. New reliable fast and cheap diagnostic algorithm resulting from the test results might improve chest pain patients' prognosis, and reduce unnecessary costs and diagnostic complications.
Frequently new onset chest pain is a sign of myocardial ischemia or even (threatening) myocardial infarction. Despite continuous improvements in diagnostic tools it can still be difficult to differentiate between a benign and a potential hazardous nature of acute chest pain. Percentages as high as 5% of chest pain patients presenting in the emergency room suffer or will suffer from myocardial infarction without being recognized as having an acute coronary syndrome (ACS) at presentation . The consequences can be disastrous, especially when these patients would not be admitted for rhythm surveillance. A component of failure to recognize threatening myocardial ischemia seems to be that discriminating non typical from typical chest pain does not differentiate well enough between threatening myocardial ischemia or not [1, 2]. Several studies have evaluated the diagnostic accuracy of a standard diagnostic flow chart to identify patients with myocardial ischemia and showed good results. Therefore, diagnostic testing at presentation or during initial hospital admittance seems warranted. Shoyeb and colleagues confirmed that patients who had diagnostic tests during initial hospital admittance had better prognosis . This is why a quick but diagnostic evaluation of new onset acute chest pain patients is needed.
New radiological techniques
One of the introduced diagnostic techniques developed is electron beam computed tomography (EBT) scan investigating the presence of coronary calcium. EBT scanning and evaluating takes less than 20 minutes , and has a low radiation load . The technique doesn't require contrast. In review and expert opinion , a negative test on coronary calcium is considered to make the presence of vulnerable plaques or obstructive coronary artery disease very unlikely. A positive test quantifies coronary atherosclerosis. It seems very clear that EBT investigations negative for calcium detection, practically rule out any risk ofa coronary event in the next years . On the other hand, high scores are related to a high cardiac risk, and occlusive coronary disease . Although calcium scores do not have an additional risk stratifying value in high risk patients , it can have a great discriminating value in intermediate risk patients . One of the recent large EBT-calcium score studies, the St. Francis Heart Study , strikingly identified high risk patients (relative risk 9.2). It was identified in patients with a calcium score >100 (a volume score). With this it was 5 times more discriminative than CRP.
Another type of CT scanning in coronary artery disease (CAD) has evolved over the last decade. Multi slice CT (MSCT) using contrast has made a true revolution in non invasive coronary imaging, resulting in near optimal coronary stenosis detection in recent studies in experienced hands and under optimal conditions . 16-slice Multi detector CT (MDCT) coronary angiography was already promising for detection of significant coronary artery disease in hospital admitted patients . With the use of 64-slice MDCT in to the hospital admitted patients the accuracy for detecting and ruling out significant coronary artery disease improved further, and non calcified plaques could be evaluated as well . Modern 64-slice MDCT has an improved resolution. Spatial resolution has improved from 1.0 × 1.0 × 0.75 millimetres voxels to 0.4 × 0.4 × 0.4 millimetres voxels at an improved temporal resolution of 188 milliseconds. This results in such a detailed and non motion artefact sub millimetre visualisation of the coronary arteries that 72% of the CT coronary angiography has exact the same result as a conventional coronary angiography. Furthermore, amount of non-assessable segments is seriously reduced . Although probably rare, a recent study using a 64-slice MDCT showed negative calcium scores in patients who did have ACS . CTA with a 64-slice MDCT might be a better investigation for ruling out ACS . It is also more cost effective than standard care as usual for low risk chest pain patients with nuclear testing.
Accurate detection of (significant) coronary stenoses could predict short-term cardiac risk. Correct identification of the nature of atherosclerotic plaques, especially cholesterol rich, dissected or thrombotic plaques could be direct proof of ACS in chest pain patients. Because of these favourable developments in EBT and MSCT investigations, we think that EBT and MSCT are promising for future use in evaluation of CAD in outpatient stable chest pain patients. Surprisingly, EBT (and MSCT) have rarely been evaluated for analysis of new onset acute chest pain patients presenting at the emergency department. To our knowledge EBT has been evaluated limited and only for short term outcome in the emergency department [17, 18]. Furthermore, in these studies calcium score was not always performed directly at presentation. Longer follow up is only evaluated in one other study with a series of 192 patients presenting with chest pain in the emergency department . A negative calcium score on EBT ruled out the chance of cardiac events during 50 months follow up, and the calcium score lowered the risk ratios of traditional risk factors. 64-slice MDCT is merely tested for new onset acute chest pain patients presenting at the emergency ward [12, 14]. 64-slice MDCT ruled out ACS when no plaques or stenosis could be detected. This further indicates that CT evaluation could be discriminating between acute chest pain patients with moderate to good prognosis, and patients with threatening or present cardiac events. Small studies in acute chest pain patients proved this [12, 14]. MSCT angiography has not been tested on a large scale and is potentially harmful because radiation and contrast exposure. Therefore, we will execute a stepwise approach. In patients with intermediate risk first a coronary calcium score with EBT will be performed. In case of an Agatston score > 10, a MSCT coronary angiography will be performed. Unfortunately EBT technology has gradually been replaced by MSCT technology, which despite a high correlation still shows considerable variation especially in the lower range . In our flowchart, in case of non cardiac cause of chest pain, MSCT will only be performed to rule out aortic dissection and pulmonary embolism a clinical suspicion. This will not be a main objective of our protocol. MSCT has already been shown successful to triple rule out all of the potentially life threatening main chest pain causes, namely aortic dissection, pulmonary artery embolism and acute coronary syndrome in small studies [21, 22]. In addition calcium scoring may overlook unstable plaques without calcification. In our protocol the patients' presentation therefore strongly guided the direction within the flow-chart. In patients with a low probability, CT angiography will be performed to rule out significant CAD only in case of a high calcium score.
There is accumulating evidence that basal inflammatory activity represents atherosclerotic disease . Therefore biomarkers reflecting inflammatory activity might represent the amount of systemic and the amount of coronary atherosclerosis at the same time. It has been suggested that inflammatory biomarkers are related to the amount of systemic and coronary atherosclerosis. We will further investigate the relationship with the calcium score. On the other hand biomarkers might have additional value on top of the calcium score. Biomarkers may reflect the unstable nature of atherosclerosis, or may induce instability itself. Adhesion molecules are necessary for plaque infiltration by inflammatory cells. Oxidative stress is an important intraplaque stimulator of inflammation. Ruptured plaques cause platelet adhesion and activation which may therefore add to the diagnostic strategy in ACS.
Myocardial ischemia is the result of ACS. A problem might be that the ECG in the acute stadium and stress testing in a later stadium may not be diagnostic. Because ischemia should be detected as early as possible because of possible lethal complications, ischemic biomarkers could be very important for diagnostic purposes. Testing of biomarkers becomes more easy, cheaper and faster, and multimarker testing in ACS has already proven prognostic value . On the other hand it has to be established for each individual biomarker that is extensively expressed in the coronary unstable plaque during ACS, whether its release into the systemic circulation is high enough for detection.
shows an overview of different biomarkers that have been tested in ACS, organized by major pathophysiologic mechanism.
asymptomatic subjects n = 1492
ACS population of Frisc trial
RR = 1.79 for CRP > 3.0 mg/L
RR = 3.40 for CRP > 10.0 mg/L
ACS patients n = 43
ACS patients of Frisc II trial n = 3269
OR = 7 for in-hosptial events
RR = 3.47 (12 month mortality) for the non-invasive group RR = 1.43 for the invasive group
Asymptomatic:RR 1.31 ACS > RR 3.5
ACS patients n = 43
OR = 11 for in hospital events
ACS n = 2270 (OPUS-TIMI16) control n = 227
HR = 1.53 for death or non-fatal MI after 10 months
n = 1229 stable/instable patients
HR = 3.3 for cardiovascular death in the highest vs. the lowest quartile
IL 10 
ACS n = 547 CAPTURE study
HR = 0.38 for death or non-fatal MI after 6 months
ACS n = 435
RR = 9.7 for 14 day mortality (quintile 5 vs quintiles 1–4)
ACS n = 965
ACS n = 985 FRISC trial
RR = 1.35 for death or non fatal MI after 6 months
RR = 2.6 for cardiac death after 2 years
ACS n = 985 FRISC trial
RR = 1.99 for cardiac death after 2 years
elective coronary angiography n = 1246
ACS n = 91 vs control n = 24
ACS n = 114
higher in cardiovascular death, not an independent predictor
elective coronary angiography n = 1246 ACS n = 91, vs control n = 24
ACS n = 114
RR = 2.8 for cardiovascular events after 2.7 years
Higher levels up till 6 months after ACS.
Levels higher in patients with MACE
OR = 4.3 for MACE (highest vs. lowest quartile)
elective coronary angiography n = 1246
ACS n = 91 vs control n = 24
ACS n = 114
higher in cardiovascular death, not an independent predictor
n = 544
OR = 3.3 for death median FU 4 years
chest pain n = 604 ACS n = 1090
4th quartile OR = 4.1 for MACE at 6 months
HR = 2.11 for death/MI at 6 months
ACS n = 446
HR = 3.08 for death/MI
CAG patients n = 504
RR = 2.47 for the presence of obstructive CAD
Fibrous cap degradation
ACS n = 33, SAP n = 17, control n = 17
serial elevation 2× normal value in ACS during 1 week
MMP 9 
ACS n = 33, SAP n = 17, control n = 17
serial elevation 2× normal value in ACS during 1 week
ACS n = 37 SAP n = 19
control n = 13
ACS n = 547
Chest pain n = 644
Higher levels in ACS versus SAP/control
OR = 2.44 for 30 day death/MI
OR = 2.32 for 30 day death/MI
Coagulation or trombocyt aggregation
STEMI n = 153
STEMI n = 86
vWF release higher in cardiovascular death
vWF release OR 6.1 for 14 day composite endpointOR = 2.0 for 30 day maortality/MI (highest quartile vs quartiles 1–3)
chest pain patients n = 626
OR = 2.71 for death/MI at 6 months
OR = 6.65
ACS n = 256)
negative predictive value = 96%
scheduled PCI n = 22
Correct prediction of ECG/troponin findings post procedure
suspected ACS n = 327
HR = 6.05 for cardiac death/non-fatal arrest in troponin negative group
chest pain n = 48
chest pain n = 107
Better prediction than CK-MB
ACS n = 1791 FRISC I
ACS n = 2019 FRISC II
OR = 3.7 for death and non-fatal MI after 30 days
HR = 4.1 for mortality after 2 years in non-invasive group
OR = 1.55 with every standard deviation rise
Profile of biomarkers and radiological markers
Biomarkers in acute chest pain patients could be related to: 1) inflammation, 2) oxidative stress; 3) fibrous cap degradation; 4) coagulation or trombocyte aggregation; 5) ischemia. The experience and opinions of which is the best biomarker reflecting one of the mentioned components in coronary syndromes is continuously changing. After inclusion of about 500 patients, we will test the biomarkers that will be considered the most reliable marker for a wide range of the mentioned components. We will use biomarkers that can be measured after defrosting, and are proven to be reliable and quickly measurable. Because opinions and measurement techniques are constantly changing, we are awaiting future developments before deciding which biomarkers are of interest .
We hypothesize that in acute chest pain patients a combination of biomarkers evaluating the above mentioned components in ACS would accurately predict the existence of advanced systemic and coronary atherosclerosis, the presence of an ACS, and the prognosis of the patients in the QICS at least one-year follow-up will be assessed by visits at the out-patient clinic and by consultation of the municipal population registry. Extreme high biomarkers values due to acute non-cardiac inflammation should be excluded. We will test individual biomarkers and a profile of biomarkers head tot head against outcome, calcium score, presentational symptoms and traditional risk factors. We will also test individual biomarkers and profiles of biomarkers on top of calcium score, presentational symptoms and traditional risk factors.
The primary objective is to evaluate whether a negative calcium score and/or a favourable biomarker profile can rule out the chance of a cardiac event in the following years. We hypothesize that EBT/MSCT and/or a biochemical profile can accurately rule out cardiac chest pain fast, (i.e. myocardial ischemia) and diagnose patients who will survive without myocardial infarctions in the following year. By ruling out myocardial ischemia it would prevent unnecessary hospital admittance and invasive or extensive ischemia testing, with all its costs and potential complications. Secondary objective is the identification of sensitive predictive markers in acute chest pain patients. We will test, presentational symptoms, traditional risk factors, individual biomarkers, a profile of biomarkers, coronary calcium score, coronary stenosis/plaque volume. Biomarkers will be retrospectively tested after defrosting of deep frozen blood taken on presentation.
In- and exclusion criteria
New onset acute chest pain without diagnostic ECG testing
If there is a diagnostic ECG for ischemia, including ST elevation myocardial infarction, no further delay is warranted and patients will be treated accordingly without CT analysis. Registration of baseline characteristics, collection of blood to be frozen and follow up will be obtained.
Exclusion criteria are
If there is diagnostic testing of a non cardiac cause of chest pain, or chest pain is evidently not cardiac, patients will be transferred to other specialists without cardiac CT testing.
The existence of a life-threatening disease with a life expectancy of less than 6 months.
All chest pain patients without exclusion criteria and without cardiac history will undergo an EBT for coronary artery calcium assessment. A coronary calcium score > 10 is considered positive and will be evaluated by ischemia testing after ruling out infarction by troponin testing 6 hours after the start of chest pain. A coronary calcium score > 400 is considered to justify MSCT testing in order to rule out CAD. Depending on MSCT results and clinical findings during further hospital admittance coronary angiography will be performed.
The prognostic value of EBT calcium score will be evaluated during follow up. In case MSCT is performed, plaque characteristics will be evaluated and related to follow up. Biomarkers will be tested and related to follow up as well as to CT findings.
Scans will be performed with an e-Speed EBT scanner (e-Speed, Imatron, San Francisco, CA, USA), in the dual 1.5 mm slice mode with an image acquisition time of 50 ms or 100 ms depending on patient size. EBT data will be collected during end-inspiratory breath hold. The non-enhanced scan will be ECG-triggered at 42% of the R-R interval. A set of 40 continuous axial coupes will be obtained starting directly under the trachea bifurcation until under the heart. Calcification will be defined as four adjacent pixels with density >130 Hounsfield units. Coronary artery calcification score will be calculated according to the method of Agatston using dedicated software.
Multislice MDCT Protocol
All patients are imaged with a 64-slice MDCT scanner (Siemens) after premeditation with oral beta-blocker and/or intravenous metoprolol when needed. Thoracic CT angiography with retrospective gating will subsequently be performed with a single biphasic injection of 130 mL of iso-osmolar contrast material (100 mL at 5 mL/sec and 30 mL at 3 mL/sec) in caudal-to-cranial acquisition. Coronary, aortic, and pulmonary arterial attenuation values will be obtained. Coronary venous and right atrial enhancement will be evaluated to assess whether there is interference with coronary artery evaluation.
Dual Source Computed Tomography: Procedure and Analysis
A retrospectively ECG-triggered DSCT scan (Somatom Definition, Siemens Medical Systems, Forchheim, Germany) with contrast enhancement will be made with a beam current of 340 mAs/rot, tube voltage of 120 kV, and a rotation time of 0.33 s for both tubes. ECG pulsing window will be 20–70% of the RR-interval for all patients. Scans will be made with a slice thickness of 3.0 mm with a 64 × 0.6 collimation. Scan direction will be was cranio-caudal starting above the coronary ostia and ending at the diaphragm below all cardiac structures. For the contrast enhanced scans 73 ml of non-ionic contrast agent (Iomeprol 400 mg I/ml, Iomeron® 400, Bracco, Italy) will be injected in an antecubital vein. Bolus triggering will be used for timing with the region of interest set in the descending aorta. A 50 ml saline bolus will follow the contrast bolus to maintain a compact bolus and to reduce the necessary amount of contrast. All patients will be treated with sublingual nitroglycerin (0.4 mg) just prior to the scan protocol.
Multi-phase reconstructions will be made to select the phase with least motion artefacts to obtain motion-free images of the coronary arteries. In this phase of the RR-interval final reconstructions will be made for evaluation. Images will be reconstructed using a B26f kernel, 0.6 slice thickness and 0.4 mm increment. 16 segments of the coronary artery will be evaluated according to the model of the American heart Association. All evaluable segments will be classified as normal (smooth borders), as having non-significant disease (luminal irregularities resulting in diameter narrowing < 50%), or as having significant stenosis (luminal diameter narrowing ≥ 50%).
This is a single center prospective open trial.
Number of patients
We will perform an interim analysis using after 100 and 500 patients.
Duration of study
Patient recruitment has started in January 2006 and is expected to be completed in July 2009. Analysis and reporting is to be completed in November 2009.
The study will take place at the University Medical Center Groningen a referral center for primary PCI in STEMI patients, serving an area in the North of the Netherlands with approximately 1,2 million inhabitants.
A multimarker strategy in the evaluation of acute chest pain patients seems promising.  In addition, non-invasive imaging in the acute setting may prove additonal value.  Combination of these two approaches may further improve diagnostic accuracy and prevent unnecessary catheterisations and reduce the number of misdiagnosed infarctions.
The present study set-up may further elucidate the value of the proposed combination of biocemical and non-invasive diagnostics.
Dr. M. Gotte initiated a protocol for chest pain patients in the Emergency Department, Mrs. M. Zijlstra helped with analysing data, Mr. H. Breukelman helped with the logistics of the blood samples, Mrs. I. Meppelder helped with the logistics at the Emergency Department.
- Kamineni R, Alpert JS: Acute coronary syndromes: initial evaluation and risk stratification. Prog Cardiovasc Dis. 2004, 46 (5): 379-392. 10.1016/j.pcad.2003.12.002.View ArticlePubMedGoogle Scholar
- Miller CD, Lindsell CJ, Khandelwal S, Chandra A, Pollack CV, Tiffany BR, et al: Is the initial diagnostic impression of "noncardiac chest pain" adequate to exclude cardiac disease?. Ann Emerg Med. 2004, 44 (6): 565-574. 10.1016/j.annemergmed.2004.03.021.View ArticlePubMedGoogle Scholar
- Shoyeb A, Bokhari S, Sullivan J, Hurley E, Miesner B, Pia R, et al: Value of definitive diagnostic testing in the evaluation of patients presenting to the emergency department with chest pain. Am J Cardiol. 2003, 91 (12): 1410-1414. 10.1016/S0002-9149(03)00390-4.View ArticlePubMedGoogle Scholar
- O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, et al: American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation. 2000, 102 (1): 126-140.View ArticlePubMedGoogle Scholar
- Hunold P, Vogt FM, Schmermund A, Debatin JF, Kerkhoff G, Budde T, et al: Radiation exposure during cardiac CT: effective doses at multi-detector row CT and electron-beam CT. Radiology. 2003, 226 (1): 145-152. 10.1148/radiol.2261011365.View ArticlePubMedGoogle Scholar
- Mitka M: Standards set for CT calcium screening but its clinical value remains unclear. JAMA. 2004, 291 (4): 408-411. 10.1001/jama.291.4.408.View ArticlePubMedGoogle Scholar
- Detrano RC, Wong ND, Doherty TM, Shavelle RM, Tang W, Ginzton LE, et al: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation. 1999, 99 (20): 2633-2638.View ArticlePubMedGoogle Scholar
- Haberl R, Becker A, Leber A, Knez A, Becker C, Lang C, et al: Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol. 2001, 37 (2): 451-457. 10.1016/S0735-1097(00)01119-0.View ArticlePubMedGoogle Scholar
- Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005, 46 (1): 158-165. 10.1016/j.jacc.2005.02.088.View ArticlePubMedGoogle Scholar
- Achenbach S: Computed tomography coronary angiography. J Am Coll Cardiol. 2006, 48 (10): 1919-1928. 10.1016/j.jacc.2006.08.012.View ArticlePubMedGoogle Scholar
- Ghersin E, Litmanovich D, Dragu R, Rispler S, Lessick J, Ofer A, et al: 16-MDCT coronary angiography versus invasive coronary angiography in acute chest pain syndrome: a blinded prospective study. AJR Am J Roentgenol. 2006, 186 (1): 177-184. 10.2214/AJR.04.1232.View ArticlePubMedGoogle Scholar
- Hoffmann U, Nagurney JT, Moselewski F, Pena A, Ferencik M, Chae CU, et al: Coronary multidetector computed tomography in the assessment of patients with acute chest pain. Circulation. 2006, 114 (21): 2251-2260. 10.1161/CIRCULATIONAHA.106.634808.View ArticlePubMedGoogle Scholar
- Kuettner A, Beck T, Drosch T, Kettering K, Heuschmid M, Burgstahler C, et al: Diagnostic accuracy of noninvasive coronary imaging using 16-detector slice spiral computed tomography with 188 ms temporal resolution. J Am Coll Cardiol. 2005, 45 (1): 123-127. 10.1016/j.jacc.2004.10.050.View ArticlePubMedGoogle Scholar
- Rubinshtein R, Halon DA, Gaspar T, Jaffe R, Karkabi B, Flugelman MY, et al: Usefulness of 64-slice cardiac computed tomographic angiography for diagnosing acute coronary syndromes and predicting clinical outcome in emergency department patients with chest pain of uncertain origin. Circulation. 2007, 115 (13): 1762-1768. 10.1161/CIRCULATIONAHA.106.618389.View ArticlePubMedGoogle Scholar
- Gallagher MJ, Ross MA, Raff GL, Goldstein JA, O'Neill WW, O'Neil B: The diagnostic accuracy of 64-slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low-risk chest pain patients. Ann Emerg Med. 2007, 49 (2): 125-136. 10.1016/j.annemergmed.2006.06.043.View ArticlePubMedGoogle Scholar
- Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, et al: Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol. 2006, 47 (3): 672-677. 10.1016/j.jacc.2005.10.058.View ArticlePubMedGoogle Scholar
- McLaughlin VV, Balogh T, Rich S: Utility of electron beam computed tomography to stratify patients presenting to the emergency room with chest pain. Am J Cardiol. 1999, 84 (3): 327-8. 10.1016/S0002-9149(99)00286-6.View ArticlePubMedGoogle Scholar
- Laudon DA, Vukov LF, Breen JF, Rumberger JA, Wollan PC, Sheedy PF: Use of electron-beam computed tomography in the evaluation of chest pain patients in the emergency department. Ann Emerg Med. 1999, 33 (1): 15-21. 10.1016/S0196-0644(99)70412-9.View ArticlePubMedGoogle Scholar
- Georgiou D, Budoff MJ, Kaufer E, Kennedy JM, Lu B, Brundage BH: Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol. 2001, 38 (1): 105-110. 10.1016/S0735-1097(01)01364-X.View ArticlePubMedGoogle Scholar
- Becker CR, Kleffel T, Crispin A, Knez A, Young J, Schoepf UJ, et al: Coronary artery calcium measurement: agreement of multirow detector and electron beam CT. AJR Am J Roentgenol. 2001, 176 (5): 1295-1298.View ArticlePubMedGoogle Scholar
- Savino G, Herzog C, Costello P, Schoepf UJ: 64 slice cardiovascular CT in the Emergency Department: concepts and first experiences. Radiol Med. 2006Google Scholar
- Jeudy J, White CS: Evaluation of acute chest pain in the emergency department: utility of multidetector computed tomography. Semin Ultrasound CT MR. 2007, 28 (2): 109-114. 10.1053/j.sult.2007.01.006.View ArticlePubMedGoogle Scholar
- Apple FS, Pearce LA, Chung A, Ler R, Murakami MM: Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2007, 53 (5): 874-881. 10.1373/clinchem.2006.080192.View ArticlePubMedGoogle Scholar
- Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000, 343 (16): 1139-1147. 10.1056/NEJM200010193431602.View ArticlePubMedGoogle Scholar
- Jaffe AS, Babuin L, Apple FS: Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006, 48 (1): 1-11. 10.1016/j.jacc.2006.02.056.View ArticlePubMedGoogle Scholar
- Dorgelo J, Willems TP, Geluk CA, van Ooijen PM, Zijlstra F, Oudkerk M: Multidetector computed tomography-guided treatment strategy in patients with non-ST elevation acute coronary syndromes: a pilot study. Eur Radiol. 2005, 15 (4): 708-713. 10.1007/s00330-004-2506-y.View ArticlePubMedGoogle Scholar
- Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004, 351 (25): 2599-2610. 10.1056/NEJMoa040967.View ArticlePubMedGoogle Scholar
- Toss H, Lindahl B, Siegbahn A, Wallentin L: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation. 1997, 96 (12): 4204-4210.View ArticlePubMedGoogle Scholar
- Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al: Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999, 99 (16): 2079-2084.View ArticlePubMedGoogle Scholar
- Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001, 286 (17): 2107-2113. 10.1001/jama.286.17.2107.View ArticlePubMedGoogle Scholar
- de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al: Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003, 107 (5): 690-695. 10.1161/01.CIR.0000049742.68848.99.View ArticlePubMedGoogle Scholar
- Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002, 106 (1): 24-30. 10.1161/01.CIR.0000020546.30940.92.View ArticlePubMedGoogle Scholar
- Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al: Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003, 107 (16): 2109-2114. 10.1161/01.CIR.0000065232.57371.25.View ArticlePubMedGoogle Scholar
- Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al: Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000, 35 (2): 358-362. 10.1016/S0735-1097(99)00574-4.View ArticlePubMedGoogle Scholar
- Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001, 104 (12): 1336-1342. 10.1161/hc3701.095949.View ArticlePubMedGoogle Scholar
- Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M: Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 2000, 36 (4): 1210-1216. 10.1016/S0735-1097(00)00824-X.View ArticlePubMedGoogle Scholar
- Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M: Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart. 2001, 85 (6): 623-627. 10.1136/heart.85.6.623.View ArticlePubMedPubMed CentralGoogle Scholar
- Rallidis LS, Gika HI, Zolindaki MG, Xydas TA, Paravolidakis KE, Velissaridou AH: Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol. 2003, 92 (10): 1195-1197. 10.1016/j.amjcard.2003.07.029.View ArticlePubMedGoogle Scholar
- Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, et al: Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol. 2006, 47 (2): 307-311. 10.1016/j.jacc.2005.08.063.View ArticlePubMedGoogle Scholar
- Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003, 108 (12): 1440-1445. 10.1161/01.CIR.0000090690.67322.51.View ArticlePubMedGoogle Scholar
- Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003, 349 (17): 1595-1604. 10.1056/NEJMoa035003.View ArticlePubMedGoogle Scholar
- Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al: Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005, 46 (7): 1249-1257. 10.1016/j.jacc.2005.06.056.View ArticlePubMedGoogle Scholar
- Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005, 353 (1): 46-57. 10.1056/NEJMoa043175.View ArticlePubMedGoogle Scholar
- Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998, 32 (2): 368-372. 10.1016/S0735-1097(98)00250-2.View ArticlePubMedGoogle Scholar
- Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, et al: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001, 345 (14): 1022-1029. 10.1056/NEJMoa003147.View ArticlePubMedGoogle Scholar
- Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM: Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005, 45 (2): 229-237. 10.1016/j.jacc.2004.09.060.View ArticlePubMedGoogle Scholar
- Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al: Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003, 108 (4): 391-394. 10.1161/01.CIR.0000083471.33820.3C.View ArticlePubMedGoogle Scholar
- Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, et al: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998, 98 (4): 294-299.View ArticlePubMedGoogle Scholar
- Heeschen C, Dimmeler S, Hamm CW, Brand van den MJ, Boersma E, Zeiher AM, et al: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003, 348 (12): 1104-1111. 10.1056/NEJMoa022600.View ArticlePubMedGoogle Scholar
- Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al: Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem. 2001, 47 (3): 464-470.PubMedGoogle Scholar
- Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A: Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996, 78 (12): 1350-1354. 10.1016/S0002-9149(96)00651-0.View ArticlePubMedGoogle Scholar
- Danne O, Mockel M, Lueders C, Mugge C, Zschunke GA, Lufft H, et al: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol. 2003, 91 (9): 1060-1067. 10.1016/S0002-9149(03)00149-8.View ArticlePubMedGoogle Scholar
- Mair J, Puschendorf B, Smidt J, Lechleitner P, Dienstl F, Noll F, et al: Early release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations. Br Heart J. 1994, 72 (2): 125-127. 10.1136/hrt.72.2.125.View ArticlePubMedPubMed CentralGoogle Scholar
- Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause EG, et al: Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem. 1995, 41 (7): 966-978.PubMedGoogle Scholar
- Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD: N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004, 110 (20): 3206-3212. 10.1161/01.CIR.0000147611.92021.2B.View ArticlePubMedGoogle Scholar
- Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al: N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003, 42 (11): 1909-1916. 10.1016/j.jacc.2003.07.015.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/9/24/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.